MaxCyte, Inc. Notice of Half Year Results (7362X)
September 02 2020 - 2:06AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7362X
MaxCyte, Inc.
02 September 2020
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Half Year Results
Gaithersburg, Maryland - 2 September 2020 - MaxCyte, Inc. (LSE:
MXCT, MXCL), a global cell-based therapies and life sciences
company, will be announcing its half year financial results for the
six months ended 30 June 2020 on Monday, 21 September 2020.
Doug Doerfler, Chief Executive Officer, will host a live
briefing for analysts at 13.00pm BST on Monday, 21 September 2020.
The presentation will be available on the Investors section of
MaxCyte's website at https://www.maxcyte.com/investors/ .
A replay file will be made available shortly afterwards via the
Company website.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered
in Gaithersburg, Maryland, US. For more information, visit
www.maxcyte.com .
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
Ashley Tapp
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORUAOBRRAUKRAR
(END) Dow Jones Newswires
September 02, 2020 02:06 ET (06:06 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024